These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 18183530)

  • 1. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The place of partial agonism in psychiatry: recent developments.
    Ohlsen RI; Pilowsky LS
    J Psychopharmacol; 2005 Jul; 19(4):408-13. PubMed ID: 15982997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs in development for the treatment of schizophrenia.
    Emsley R
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1103-18. PubMed ID: 19589093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment?].
    Anil Yağcioğlu AE
    Turk Psikiyatri Derg; 2007; 18(4):364-74. PubMed ID: 18066727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacology of second-generation antipsychotics: a validity of the serotonin-dopamine hypothesis].
    Kuroki T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Oct; 24(5):257-64. PubMed ID: 15658501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New targets for antipsychotics.
    Jones HM; Pilowsky LS
    Expert Rev Neurother; 2002 Jan; 2(1):61-8. PubMed ID: 19811016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half a century of antipsychotics and still a central role for dopamine D2 receptors.
    Kapur S; Mamo D
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1081-90. PubMed ID: 14642968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.